Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
UroMems Initiates First-in-Human Study of Its Smart Implant to Treat Stress Urinary Incontinence
UroMems, a global company developing breakthrough, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-in-human implant of the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) investigational device to treat SUI. This initial clinical study is a key milestone in the development of UroActive. Read more.
Source: PRNewswire, November 29, 2022
FDA Classifies Baxter’s Hospital Bed System Recall As Most Serious
The U.S. health regulator on Wednesday classified the recall of hospital bed systems by Baxter International Inc (BAX.N), as the most serious type, on concerns it could lead to life-threatening injuries or death. Baxter initiated the recall of its WatchCare Incontinence Management System, which is used to discreetly alert an incontinent patient’s caregiver of involuntary urination or defecation, by sending a correction letter to its customers in late September. Read more.
Source: Reuters, November 23, 2022
Coloplast to Introduce SpeediCath Flex Set Catheter in US
Danish medical device company Coloplast is set to launch its new SpeediCath Flex Set catheter in the US this month. The new catheter is a gentle, all-in-one solution that has been developed for people living with bladder and urinary problems. It features a no-touch dry sleeve as well as an omnidirectional tip, which can bend to follow the curves of the urethra. The SpeediCath Flex Set has a soft-squeeze grip that safely guides the tip into the urethra without making contact. It helps patients catheterise at home or away and also supports them in managing conditions and sustaining healthy lifestyles. Read more.
Source: Medical Device Network, November 21, 2022
TENA Launches Lights Sensitive Ultra Pads Tackling a Lesser-Known Menopause Symptom
TENA, the UKs leading incontinence brand for over 60 years, has launched a new range of Lights Sensitive Ultra Pads, designed to manage bladder leaks and support healthy intimate skin. This latest product innovation features a unique skin caring emulsion that has been specifically designed for sensitive skin by helping to limit friction, making it the first of its kind to the UK market. Continuing in its mission to better support women during the menopause, the introduction of the TENA Lights Sensitive Ultra will help the large number of women who suffer with skin irritation and incontinence – two of the many lesser-known menopausal symptoms. Read more.
Source: Retail Times, November 19, 2022
PBE, Elizabeth Dole Foundation Exceed Goal to Benefit Veterans, Caregivers by Nearly $100,000
Ohio-based incontinence product manufacturer Principle Business Enterprises, Inc. (PBE), and the Elizabeth Dole Foundation, a Washington, DC, nonprofit that advocates for military caregivers, exceeded their joint goal for a year-long fundraising drive, with contributions totaling $295,000 to provide essential relief to these “Hidden Heroes.” Earmarked for the foundation’s “Respite Relief for Military and Veteran Caregivers” program that gives qualifying caretakers a much-needed break, the money will directly benefit an estimated 340 military families and indirectly impact more than 1000 individuals. Respite Relief recipients – spouses, parents, relatives and friends who take care of America’s wounded, ill and injured veterans – enjoy 35 hours of free help from in-home care professionals. Read more.
Source Nonwovens Industry, November 18, 2022
Urinary Tract Infections: A New Antibiotic May Be on the Way to Treat UTIs
A new type of antibiotic for treating urinary tract infections (UTIs) may be available sooner than expected. Gepotidacin, manufactured by the pharmaceutical company GSK, is being described as “novel” or “first-in-class” because of how it works to prevent or slow bacterial DNA replication. If approved, gepotidacin would be the first new antibiotic developed for treating UTIs in more than 20 years. It would also be available at least a year ahead of the estimated study completion date. Read more.
Source: healthline, November 8, 2022
BioDerm, Inc. Begins Distribution in Home Care Markets of a New Revolutionary Female Incontinence Device From TillaCare, Ltd
BioDerm is excited to partner with TillaCare as a U.S. distributor of TillaCare’s UriCap Female. UriCap Female is a revolutionary external urine collection system offering female patients with urinary incontinence a comfortable, easy-to-use solution without the skin irritation and discomfort associated with absorbent products. Following the successful launch of UriCap Female in hospital and institutional settings, BioDerm launched a direct-to-consumer campaign allowing patients to receive UriCap Female for in-home use. Read more.
Source: Index-Journal, October 28, 2022